替莫唑胺
贝伐单抗
胶质母细胞瘤
医学
肿瘤科
内科学
持续时间(音乐)
癌症研究
化疗
文学类
艺术
作者
Mehmet Beşiroğlu,Tarık Demir,Abdallah TM Shbair,Ayşe İrem Yasin,Atakan Topçu,Hacı Mehmet Türk,Mehmet Beşiroğlu
标识
DOI:10.29271/jcpsp.2021.08.932
摘要
Duration of first-line TMZ treatment was not a predictor for OS of the GBM patients, who were treated with Beva as second-line setting. Key Words: Bevacizumab, Duration of treatment, Glioblastoma multiforme, Predictive score, Temozolomide.
科研通智能强力驱动
Strongly Powered by AbleSci AI